Roswell Park Comprehensive Cancer Center hematology experts from many disciplines and subspecialties were invited to present new research at the American Society of Hematology (ASH) 60th Annual Meeting, which begins today and continues through Tuesday, Dec. 4, in San Diego, California. The dozens of research projects they will highlight include new research on management of aggressive and rare lymphomas, approaches for optimizing cellular therapies such as blood and marrow transplant, and decision-making around genomic testing for patients with acute myeloid leukemia.

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented earlier this month at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented Friday at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.

The Buffalo Sabres today announced the team, in partnership with Roswell Park Comprehensive Cancer Center, will again take part in the NHL’s Hockey Fights Cancer™ program during the team’s home game against the San Jose Sharks on Tuesday, Nov. 27, at 7 p.m.